Opto Circuits up 14%, arm gets USFDA nod Powerheart G5 AED

Moneycontrol Bureau

Investors bought more shares of Opto Circuits India on Wednesday after its subsidiary received approval from the USFDA for its Powerheart G5 AED with CRPD. The stock rallied 14 percent intraday.

Cardiac Science Corporation said Powerheart G5 AED with CRPD has received 510(k) market clearance from the US Food and Drug Administration (USFDA), allowing the company to begin selling the AED with CPRD along with its Powerheart G3 and G5 product line.

Cardiac Science is a group company of Opto Circuits and a global leader in automated external defibrillators (AEDs).

"This news is a testament to the commitment shown by our employees who have spent many years of developing, testing and refining the Powerheart G5 so that seasoned and first-time rescuers will have the most reliable, easy-to-use AED in the US marketplace," said Vinod Ramnani, chairman and managing director, Opto Circuits.

The Powerheart family of AEDs is designed to enable rescuers to swiftly provide effective, life-saving therapy to aid a person who has suffered sudden cardiac arrest (SCA), a condition in which the heart suddenly stops beating due to ill regularities in its electrical system.

Cardiac Science has been working to reduce SCA fatalities since it introduced the first fully automated external defibrillator.

The Powerheart G5 with CPRD will be available for purchase in the United States later this year, said Cardiac.

At 13:18 hours IST, the scrip of Opto Circuits India was quoting at Rs 21.25, up Rs 1.55, or 7.87 percent on the BSE.